Session: P-20. COVID-19 Pathogenesis

Background. Until now, studies have been focused on patient-centered risk factors, while SARS-CoV-2 aggressiveness has been established as causing 20% of severe and critical patients. However, there are still many unanswered questions concerning the clinical aggressiveness behavior of SARS-CoV-2. This study focuses on progression of symptoms as a marker of such aggressiveness, using the Period between initial symptoms and clinical progression to COVID-19 suspicion (PISYCS) to determine the risk of severe disease and mortality.

Methods. Historic cohort study of Mexican patients. Data from January-April 2020 were provided by the Health Ministry. Setting: Population-based. Participants registered in the Epidemiologic Surveillance System in Mexico. Participants were subjects who sought medical attention for clinical suspicion of COVID-19. All patients were subjected to RT-PCR testing for SARS-CoV-2. We measured the Period between initial symptoms and clinical progression to COVID-19 suspicion (PISYCS) and compared it to the primary outcomes (mortality and pneumonia).

Results. 65,500 patients were included. Reported fatalities and pneumonia were 2.76% (3.32%), and 11,568 (17.66%), respectively. According to the PISYCS, patients were distributed as follows: 14.89% in < 24 hours, 43.25% between 1–3 days, 31.87% between 4–7 days and 9.97% > 7 days. The distribution for mortality and pneumonia was 5.2% and 22.5% in < 24 hours, 2.5% and 14% between 1–3 days, 3.6% and 19.5% between 4–7 days, 4.3% and 20.6% > 7 days, respectively (p < 0.001). Adjusted risk of mortality was (OR [95% CI], p-value): < 24 hours = 1.75 [1.55–1.98], p < 0.001; 24–48 hours = 1.48 [1.41–1.56], p < 0.001; > 48 hours = 1.57 [1.46–1.69], p < 0.001.

Risk of Mortality vs. PISYCS

Logistic regression analysis of mortality based on PISYCS. Note that risk of mortality is significantly higher when PISYCS is > 24 hours and < 7 days.

Risk of Pneumonia vs. PISYCS

Logistic regression analysis of developing pneumonia based on PISYCS. Note that risk of pneumonia is significantly higher when PISYCS is > 24 hours and < 7 days.

Conclusion. The PISYCS shows a U-shaped SARS-CoV-2 aggressiveness pattern. Further studies are needed to corroborate the time-related pathophysiology behind these findings and possibly justify use of PISYCS as an initial evaluation tool and therapy/monitoring in high-risk patients.

Disclosures. All Authors: No reported disclosures

437. Longitudinal Plasma Cytokine Profiles Differentiating COVID-19 Severity Groups

Amanda M. Green, MD1; Aisha Souque, PhD2; Mona Agrawal, PhD2; Joshua Wolf, MBBS, PhD, FRACP3; Joshua Wolf, MBBS, PhD, FRACP3; Aditya Gaur, MD, MS2; Kim J. Allison, RN1; Jeremie Esterp, MD3; Emma Allen, PhD4; Paul Thomas, PhD5; Heather Smallwood, PhD5; St Jude Children’s Research Institute, Memphis, Tennessee; 2University of Tennessee Health Science Center, Memphis, Tennessee; 3St. Jude’s Children’s Research Hospital, Memphis, TN; 4St Jude Children’s Research Hospital, Memphis, Tennessee; 5St Jude Children’s Research Hospital, Memphis, TN

Session: P-20. COVID-19 Pathogenesis

Background. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), an infection with widely varying clinical severity. Severe COVID-19 was initially proposed to be secondary to cytokine storm syndrome (CSS). However, studies since showed that patients with severe COVID-19 rarely display CSS cytokine phenotypes, and may have more limited inflammatory responses instead.

Methods. Prospective cohorts, aged 0-90 years of age who tested positive by polymerase chain reaction (PCR) for SARS-CoV-2 were enrolled from inpatient hospitals and outpatient testing centers in Memphis, TN from May 2020-January 2021. Longitudinal blood samples were obtained including acute, sub-acute and convalescent timepoints. Severity scores of asymptomatic, mild, moderate, and severe COVID-19 were assigned at time of convalescent assessment. Plasma was analyzed with a quantitative human magnetic 38-plex cytokine assay.

Results: 169 participants were enrolled, including 8 asymptomatic, 117 mild, 22 moderate and 17 severe cases, and 5 children with post-COVID-19 multisystem inflammatory syndrome in children (MIS-C). All moderate and severe patients were hospitalized and received treatment (39%). Clear distinctions were seen between asymptomatic-mild cases and moderate-severe cases at acute timepoints and during disease progression for GCSF, IL-8, IL-10, IL-15, IL-18a, IP-10, MIP-1a, MIP-1b, TGFα. There was a significant difference between participants who did and did not require hospitalization for acute timepoint levels of IL-10, IL-15, MIP-1β and TGFα (p < 0.01). Only 4 participants with active COVID-19 were found to meet criteria for CSS (3%), only 3 of which were severe. MIS-C participants showed nearly universally elevated cytokine levels compared to those with active COVID-19.

Temporal and severity associations of IL-10 and IP-10

Figure 1. Temporal and severity associations of IL-10 and IP-10 Examples of differentiating cytokine profiles by severity and time. Among SARS-CoV-2 PCR positive participants, IL-10 and IP-10 displayed increased levels in their acute plasma samples as clinical severity increased A,C. IL-10 and IP-10 also showed distinct time dependent responses (ln(Cytokine level (pg/mL)) that differentiated the more severe from the less severe groups B,D.

Conclusion. Moderate and severe acute COVID-19 has a distinct cytokine profile from asymptomatic and mild cases, as detected from acute, subacute and convalescent plasma.

Disclosures. Joshua Wolf, MBBS, PhD, FRACP, Karius Inc. (Research Grant or Support) Joshua Wolf, MBBS, PhD, FRACP, Nothing to disclose Paul Thomas, PhD, Cytoagents (Consultant) Immunoscope (Consultant)

438. Phenotypic Differences Between Distinct Immune Biomarker Clusters During the ‘Hyperinflammatory’ Middle-Phase of COVID-19

Paul W. Blair, MD MHS MSPH1; Joost Branda, PhD2; Nsurat J. Epsi, n/a; Stephanie A. Richard, PhD, MHS1; Deborah Striegel, PhD3; Josh Chenoweth, PhD2; Rittal Mehta, MS3; Emily Clemens, MS3; Allison Malloy, MD1; Charlotte Lantieri, PhD1; I. Stephen Dumeral, MD1; David Trumble, MD, DrPH1; Timothy Burgess, MD, MPH1; Simon Pollett, MBBS2; Brian Agan, MD3; Danielle Clark, PhD4; 1Uniformed Services University, Bethesda, Maryland; 2Henry
Machine learning clustering methods are promising analytical tools for identifying inflammation marker patterns associated with baseline risk factors and severe illness due to COVID-19. These approaches may offer new insights for COVID-19 prognosis, therapy, and prevention.

Disclosures.
Simone Polletti, MBBS, Astra Zeneca (Other Financial or Material Support, HJF; in support of USU I2CRF, funded under a CRADA to augment the conduct of an unrelated Phase III COVID-19 vaccine trial sponsored by AstraZeneca as part of USG response (unrelated work)).